FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
Historical Prices
From:
To:
About
ceo
Mr. Grant E. Pickering M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://vaxcyte.comexchange
NASDAQ
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc....
CIK
0001649094
ISIN
US92243G1085
CUSIP
92243G108
Address
825 Industrial Road
Phone
650 837 0111
Country
US
Employee
414
IPO Date
Jun 12, 2020
Financial Statement
Earnings
PCVX Financial Summary
CIK
0001649094
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
92243G108
ISIN
US92243G1085
Country
US
Price
74.37
Beta
1.02
Volume Avg.
1.19M
Market Cap
9.58B
Shares
-
52-Week
58.1-121.055
DCF
2.23
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-19.57
P/B
-
Website
https://vaxcyte.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PCVX News
Zacks Investment Research
Jul 31, 2024
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): ...
The consensus price target hints at a 25.2% upside potential for Vaxcyte (PCVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research
Jul 29, 2024
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (...
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
GlobeNewsWire
Apr 2, 2024
Vaxcyte to Present at the 23rd Annual Needham Virtual Health...
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.
Zacks Investment Research
Feb 28, 2024
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Shoul...
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research
Feb 26, 2024
Why Vaxcyte (PCVX) Might Surprise This Earnings Season
Vaxcyte (PCVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks Investment Research
Feb 26, 2024
5 Stocks to Buy That Are Poised to Beat on Earnings This Wee...
We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.
GlobeNewsWire
Feb 15, 2024
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financia...
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial ...
GlobeNewsWire
Feb 1, 2024
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th ...
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.
